Policies & Disclaimers  |  Contact Us  |  Site Map  |  Important Safety Information   
Inhaled Ventavis® (iloprost) Inhalation Solution Breathe In the Power of Prostacyclin In Pulmonary Arterial Hypertension (PAH) NYHA Class III or IV
PAH Pathways - Actelion Services & Support
Download 20 mcg/mL Medication Order Form
Download the
Ventavis Patient
Enrollment Forms

Contact Us

Actelion Pharmaceuticals US, Inc.
5000 Shoreline Court, Suite 200
South San Francisco, CA 94080
1.866.228.3546 Phone
415.268.9515 Fax

Medical Information

For further medical information on Ventavis or PAH, please contact our Medical Information Department by calling 1.866.228.3546 or by sending a fax to 415.268.9515. Contact us via e-mail at: usmedinfo@actelion.com.

The hours of operation for the Medical Information Department are 9:00 a.m. to 5:00 p.m. PST, Monday through Friday excluding holidays.

For information on ongoing patient support and education, contact Sure Steps™ at 1-877-STEPS-50 (1-877-783-7750)—Monday through Friday, between 8 a.m. and 11 p.m. Eastern Time.



* In the AIR pivotal trial, Ventavis delivered significant patient improvement in a composite endpoint consisting of ≥10% increase in 6MWD, improvement in NYHA functional class, and lack of deterioration or death (p=0.0033).

IMPORTANT SAFETY INFORMATION:
In clinical studies, common adverse reactions due to Ventavis included vasodilation (flushing), cough, headache, trismus, and insomnia. Serious adverse events reported at a rate of less than 3% included congestive heart failure, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, and kidney failure. Vital signs should be monitored while initiating Ventavis. Ventavis should not be initiated in patients with systolic blood pressure less than 85 mmHg. Stop Ventavis immediately if signs of pulmonary edema occur; this may be a sign of pulmonary venous hypertension.

Please see full Prescribing Information

For more information about
Ventavis, please call
1-866-ACTELION (1-866-228-3546).

Policies & Disclaimers  |  Contact Us  |  Site Map  |  Important Safety Information

THIS SITE IS INTENDED FOR U.S. AUDIENCES ONLY.
SECOND WIND is a licensed trademark of Pulmonary Rehabilitation Associates.
©2010 Actelion Pharmaceuticals US, Inc. All rights reserved.

ACTELION